candesartan has been researched along with Recrudescence in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It was our aim to study the levels of L-arginine, the substrate for nitric oxide and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, and their relation to the maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), as well as the effects of angiotensin receptor blockade on these variables." | 9.14 | L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Bratseth, V; Seljeflot, I; Smith, P; Tveit, A, 2010) |
| "Inflammatory markers, their relation to maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), and the effect of candesartan were investigated in a double-blind placebo-controlled study (CAPRAF)." | 9.12 | Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2007) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke." | 5.16 | Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. ( Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012) |
| "It was our aim to study the levels of L-arginine, the substrate for nitric oxide and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, and their relation to the maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), as well as the effects of angiotensin receptor blockade on these variables." | 5.14 | L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Bratseth, V; Seljeflot, I; Smith, P; Tveit, A, 2010) |
| "Inflammatory markers, their relation to maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), and the effect of candesartan were investigated in a double-blind placebo-controlled study (CAPRAF)." | 5.12 | Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2007) |
| " We subsequently used full dose ramipril, candesartan and aliskiren under a close monitoring of kidney function and electrolytes and examined the effect on proteinuria, clinical course and tolerability over 12 months." | 3.75 | Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. ( Amann, K; Frank, H; Freiberger, V; Heemann, U, 2009) |
| "Treatment with candesartan had no influence on serum YKL-40 levels." | 2.78 | Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Seljeflot, I; Smith, P; Svendsen, JH; Tveit, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tveit, A | 3 |
| Seljeflot, I | 3 |
| Smith, P | 3 |
| Arnesen, H | 3 |
| Svendsen, JH | 1 |
| Freiberger, V | 1 |
| Amann, K | 1 |
| Heemann, U | 1 |
| Frank, H | 1 |
| Bratseth, V | 1 |
| Sandset, EC | 1 |
| Murray, GD | 1 |
| Bath, PM | 1 |
| Kjeldsen, SE | 1 |
| Berge, E | 1 |
| Persson, H | 1 |
| Swedberg, K | 1 |
| Grundvold, I | 1 |
| Abdelnoor, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for candesartan and Recrudescence
| Article | Year |
|---|---|
Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
Topics: Adipokines; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atrial Fibrillation; Atrial R | 2013 |
L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Atrial Fibrillation; Benzimidazoles; Biphen | 2010 |
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2012 |
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biph | 2007 |
2 other studies available for candesartan and Recrudescence
| Article | Year |
|---|---|
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
Topics: Adult; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2009 |
[Candesartan reduces the risk of mortality and recurrence of chronic heart failure. Important results from the CHARM study].
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |